Compare · EAF vs TMO
EAF vs TMO
Side-by-side comparison of GrafTech International Ltd. (EAF) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- EAF operates in Energy, while TMO operates in Industrials - the two are in different parts of the market.
- TMO is the larger of the two at $177.93B, about 805.5x EAF ($220.9M).
- Over the past year, EAF is up 44.4% and TMO is up 14.2% - EAF leads by 30.1 points.
- TMO has been more active in the news (9 items in the past 4 weeks vs 1 for EAF).
- TMO has more recent analyst coverage (25 ratings vs 6 for EAF).
- Company
- GrafTech International Ltd.
- Thermo Fisher Scientific Inc
- Price
- $8.56-0.81%
- $479.36+2.79%
- Market cap
- $220.9M
- $177.93B
- 1M return
- +25.61%
- -2.51%
- 1Y return
- +44.35%
- +14.23%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NYSE
- NYSE
- IPO
- 2018
- News (4w)
- 1
- 9
- Recent ratings
- 6
- 25
GrafTech International Ltd.
GrafTech International Ltd. researches, develops, manufactures, and sells graphite and carbon based products worldwide. It offers graphite electrodes to produce electric arc furnace steel and other ferrous and non-ferrous metals; and petroleum needle coke, a crystalline form of carbon used in the production of graphite electrodes. The company sells its products primarily through direct sales force, independent sales representatives, and distributors. GrafTech International Ltd. was founded in 1886 and is headquartered in Brooklyn Heights, Ohio.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest EAF
- GrafTech International downgraded by Analyst
- GrafTech Announces First Quarter 2026 Earnings Conference Call and Webcast
- SEC Form 4 filed by Germain Jean-Marc
- SEC Form 4 filed by Shivaram Sachin M
- SEC Form 4 filed by Roegner Eric V
- SEC Form D filed by GrafTech International Ltd.
- SEC Form DEFA14A filed by GrafTech International Ltd.
- SEC Form DEF 14A filed by GrafTech International Ltd.
- GrafTech Announces Graphite Electrode Price Increase
- SVP, Commercial and CTS Perez Ortiz Inigo converted options into 10,144 shares, increasing direct ownership by 28% to 46,226 units (SEC Form 4)
Latest TMO
- President & COO Pettiti Gianluca sold $185,064 worth of shares (400 units at $462.66) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,051 units (SEC Form 4)
- Thermo Fisher Scientific to Host Investor Day
- Thermo Fisher Scientific Signs Agreement to Sell its Microbiology Business to Astorg
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Thermo Fisher Scientific Reports First Quarter 2026 Results
- AI-Powered Pharma Manufacturing Signals Scalable Efficiency, Long-Term Cost Advantages
- Thermo Fisher Scientific Expands Global Biobank Leadership Through Strategic Collaboration with PRECISE-SG100K Singapore to Advance Population-Scale Proteomics
- SEC Form DEFA14A filed by Thermo Fisher Scientific Inc
- SEC Form DEF 14A filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026